Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.
According to the company, a conference call to discuss results will be held on February 17, 2026 at 1:30pm PT / 4:30pm ET, with live webcast and replay available via Halozyme's Investors website.
Details
News Market Reaction – HALO
On Feb 11, the first trading day after this news, HALO closed 0.89% below the previous close.
Data tracked by StockTitan Argus for the Feb 11 session.
Key Figures
- Earnings release date
- February 17, 2026
- Scheduled fourth quarter and full-year 2025 results release
- Conference call time
- 1:30pm PT / 4:30pm ET
- Time for results conference call on February 17, 2026
Historical Context
-
Raised 2025 estimates and 2026 multi-year financial guidance with higher revenue.
-
Scheduled call to present preliminary 2025 revenue and extended 2026–2028 guidance.
-
Global ENHANZE® collaboration and license for vedolizumab with potential royalties.
-
FDA approved RYBREVANT FASPRO™ with ENHANZE® for EGFR-mutated NSCLC.
-
Election of Jim Lang to the board, adding healthcare and analytics experience.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2025-financial-and-operating-results-302684270.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.